Diligence memo · auto-generated · as of July 2, 2026
SignPath Pharma, Inc.
SignPath Pharma, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
SignPath Pharma, Inc. operates in Pharmaceuticals, based in Sandy.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SignPath Pharma, Inc. has raised $12M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.4M on 2013-03-13.
Most recent recorded round closed around 2020-06-01.
Valuation (modeled)modeled
Provath models SignPath Pharma, Inc. at approximately $48M (range $1.8M–$263M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.32× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 6.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 57% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 43% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.